Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

Evan A. Stein, Kristina Strutt, Harry Southworth, Peter J. Diggle, Elinor Miller

Research output: Contribution to journalArticle

Abstract

Heterozygous familial hypercholesterolemia (HFH) is a common genetic disorder that confers a significantly increased risk of early coronary artery disease. This study compared atorvastatin and rosuvastatin in reducing low-density lipoprotein (LDL) cholesterol in HFH in a global, 18-week, weighted-randomization, double-blind, parallel-group, forced-titration study. Following a 6-week diet lead-in, 623 patients were randomized to 20 mg/day of atorvastatin (n = 187) or rosuvastatin (n = 436) with forced titration at 6-week intervals to 80 mg/day. The primary end point was percentage change in LDL cholesterol from baseline to week 18. At week 18, rosuvastatin therapy produced a significantly greater reduction in LDL cholesterol than atorvastatin (-57.9% vs -50.4%; p

Original languageEnglish (US)
Pages (from-to)1287-1293
Number of pages7
JournalThe American Journal of Cardiology
Volume92
Issue number11
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia'. Together they form a unique fingerprint.

  • Cite this